Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, will showcase ongoing studies and data on chimeric antigen receptor T cell therapy, immunotherapy against solid tumors and more at the American Association for Cancer Research annual meeting from March 29 through April 3 in Atlanta.
Ludwig Cancer Research released today the full breadth of findings to be presented by Ludwig researchers at this year's American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Ga., March 29 - April 3, 2019.
Advances in genetics and genomics have taught us that every single tumor is different, and yet most standard therapies treat them all in the same way, limiting the effectiveness of treatments offered to many cancer patients.
Researchers have engineered "antibody-like" T cell receptors that can specifically stick to cells infected with cytomegalovirus, or CMV, a virus that causes lifelong infection in more than half of all adults by age 40.
With their ability to treat a wide a variety of diseases, spherical nucleic acids (SNAs) are poised to revolutionize medicine. But before these digitally designed nanostructures can reach their full potential, researchers need to optimize their various components.
Cancer researchers at the University of Bonn have reported significant progress in the treatment of glioblastoma. About one third of all patients suffer from a particular variant of this most common and aggressive brain tumor.
Columbia researchers have learned why some glioblastomas--the most common type of brain cancer--respond to immunotherapy. The findings could help identify patients who are most likely to benefit from treatment with immunotherapy drugs and lead to the development of more broadly effective treatments.
A UCLA-led study suggests that for people with recurrent glioblastoma, administering an immunotherapy drug before surgery is more effective than using the drug afterward.
Around a glioblastoma, a very aggressive brain tumor, cells of the human immune system start helping the tumor instead of attacking it. To do research on what happens in the interaction of these cells, scientists of the University of Twente now created a 3D-bioprinted mini model of the brain.
A breakthrough for brain tumor drug development and personalized medicine published today in Nature Scientific Reports.
Following a California Institute for Regenerative Medicine Independent Citizens Oversight Committee meeting held last week, University of California, Irvine researchers learned they will receive $6 million in funding to support the continued development of a promising new treatment for Huntington's disease
A study led by investigators from Massachusetts General Hospital (MGH) and the University of Cyprus reveals details of a way the dangerous brain tumors called glioblastomas resist the effects of antiangiogenic drugs designed to cut off their blood supply.
Corning Incorporated will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including those for high throughput screening and ADME/toxicology at the upcoming Society for Laboratory Automation and Screening conference, held February 2-6 in Washington, D.C.
Researchers at The University of Texas MD Anderson Cancer Center have discovered an immune regulator that appears to dictate glioblastoma progression by shutting down immune surveillance, indicating a potential new area of therapeutic investigation.
The Damon Runyon Cancer Research Foundation announced that nine scientists with novel approaches to fighting cancer have been named 2019 recipients of the Damon Runyon-Rachleff Innovation Award.
A Massachusetts General Hospital-led research team has demonstrated, for the first time, how solid stress - the physical forces exerted by the solid components of a tumor - impacts the tissue surrounding brain tumors and contributes to resulting neurological dysfunction and neuronal cell death.
Scientists have discovered molecular signatures that reveal why women are more likely to develop and die from the brain cancer, glioblastoma.
An interview with Dr. Tim Steppe, discussing the latest advances in the CLARITY technique and his top tips for scientists using this method in their research.
The European Organisation for Research and Treatment of Cancer Brain Tumor Group and Protagen AG today announced a collaboration to utilize Protagen’s Cancer Immunotherapy Array to identify autoantibody biomarkers that investigate the immunological profile and immuno-competence of long-term Glioblastoma survivors.
How does cancer spread? While studying human brain tumor cells, a team of scientists at the Research Institute of the McGill University Health Centre found some answers to this crucial, yet so far unanswered question.